Does absence of the APOE ε2 allele increase ApoB and LDL particle burden?

The APOE ε2 allele is recognized as a significant genetic modulator of lipid profiles, primarily known for its association with lower low-density lipoprotein cholesterol (LDL-C). Research consistently shows that individuals carrying at least one ε2 allele exhibit a lower cardiovascular risk profile regarding LDL-C compared to those with the more common ε3 or ε4 alleles.

Clinical and genomic evidence

Large-scale population studies and meta-analyses, including data from over 49,000 individuals, confirm that APOE ε2 carriers (heterozygotes and most homozygotes) maintain significantly lower total cholesterol and LDL-C concentrations than ε3 carriers.

• LDL-C reduction: Carrying the ε2 allele is associated with an absolute LDL-C reduction of approximately 0.44 mmol/L (~7-8%) compared to the ε3/ε3 genotype.
• ApoB and particle burden: Evidence from cohort studies indicates that the absence of the ε2 allele (typically found in ε3/ε3 or ε4 carriers) results in higher levels of Apolipoprotein B (ApoB). Because each LDL and VLDL particle contains one molecule of ApoB-100, higher ApoB levels directly reflect an increased burden of atherogenic particles.
• Risk differentiation: While ε2 is protective against high LDL-C, individuals carrying the ε4 allele (who also lack ε2) often exhibit the highest levels of small dense LDL (sdLDL) and oxidized LDL, further increasing particle-related cardiovascular risk.

Mechanistic explanations

The LDL-lowering effect of the ε2 allele is driven by a unique biochemical "binding defect" in the ApoE2 protein.

• Binding affinity: The ε2 allele (characterized by an Arg158Cys substitution) produces a protein with only 1-2% of the binding affinity for the hepatic LDL receptor (LDLR) compared to the standard ApoE3 protein.
• Remnant dynamics: This defect paradoxically lowers LDL-C by impairing the conversion of VLDL and IDL remnants into LDL particles. Instead of being efficiently processed into LDL, these remnants are cleared or remain as larger particles, which leads to a lower steady-state production of circulating LDL.
• Compensatory response: The liver may also downregulate the production of VLDL in response to these altered dynamics, further contributing to the overall reduction in the circulating LDL particle burden.

Bottom line

The absence of the APOE ε2 allele removes a significant genetically driven LDL-lowering influence. Individuals lacking this allele, particularly ε3 or ε4 carriers, tend to have higher circulating levels of ApoB and a higher LDL particle burden due to the efficient conversion of precursor lipoproteins into LDL.